unique and patented substance
for cardio-metabolic indications
Cortria Corporation is a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular and metabolic diseases. Cortria is based in Boston, MA.
The Company collaborates with leading clinics and academic institutions around the world.
The core activity of Cortria is investing in research and development. The company’s core value is caring for the health of patients by ensuring safety and the highest quality of our products.
Cortria is developing an innovative drug candidate for cardio-metabolic indications.
Our drug candidate has been investigated in phase I and in 14-week Randomized, Double-Blind, Placebo-Controlled, Forced Dose-Escalation, Multi-Center Study.
The well-tolerance and safety profile of our drug candidate were confirmed in this study. In addition, it did not evoke the characteristic nicotinic acid adverse events of erythema and hot flush.
Our drug candidate is an interesting anti-inflammatory and metabolic modifying drug candidate. Pre-clinical and clinical studies demonstrate that our drug candidate:
• reduces inflammatory markers, hsCRP and TNF-alpha,
• stimulates production of prostacyclin (PGI2),
• improves vascular endothelial function,
• increases lipoprotein lipase activity,
• increases adiponectin level,
• reduces trigliceride (TG) blood level,
• extends lifespan in model of aging.
Our drug candidate may provide a potential new standard of care for the treatment of cardio-metabolic disorders.
The clinical results from Phase II study warrant further investigations for our drug candidate in cardio-metabolic diseases:
• coronary artery disease,
• pulmonary arterial disease,
• non-alcoholic steatohepatitis,